Previous close | 5.65 |
Open | 5.60 |
Bid | 5.40 |
Ask | 5.50 |
Strike | 150.00 |
Expiry date | 2023-08-18 |
Day's range | 5.50 - 5.70 |
Contract range | N/A |
Volume | |
Open interest | 945 |
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.